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A B S T R A C T
Objective: To analyse all cases of Nocardia pneumonia occurring between 2010 and 2016 in five Spanish
hospitals.
Methods: This was a retrospective observational analysis of clinical and microbiological data collected
from 55 cases of Nocardia pneumonia.
Results: There were one to 20 cases per hospital and six to nine cases per year. Chronic obstructive
pulmonary disease, bronchiectasis, and asthma were the main predisposing underlying respiratory
conditions. Thirty-four patients were receiving systemic and/or inhaled corticosteroids prior to infection,
eight had neoplasia, and six had haematological malignancies. Clinical and radiological findings were
common to pneumonia of other infectious aetiologies, except for the frequent presence of nodules and
cavitation. Overall, the 1-year mortality was high (38.2%), and mortality was directly related to the
pulmonary disease in 15 patients (27.3%). The most frequently identified species were N. cyriacigeorgica
(n = 21), N. abscessus (n = 8), and N. farcinica (n = 5). All Nocardia isolates were susceptible to linezolid and
all but two were susceptible to amikacin and trimethoprim–sulfamethoxazole.
Conclusions: Nocardia pneumonia-associated mortality remains high, probably because of the debilitated
status of patients in whom this pathogen is able to cause pulmonary infection.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Nocardia species are gram-positive aerobic actinomycetes
commonly found in soil. To date, 119 Nocardia species have been
described (Parte, 2018), and although all are potentially patho-
genic (Ercibengoa et al., 2016), only a small proportion have been
described as responsible for human infections. According to theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1






Lung carcinoma 2 3.6
Previous pneumonia 2 3.6
Other conditions
Cardiovascular disease 18 32.7
Diabetes 10 18.2
Chronic renal failure 9 16.4
Neoplasiaa 7 12.7
Haematological malignancies 6 10.9
Liver disease 5 9.1
HCV infection 2 3.6
Chronic gastritis 1 1.8
Immunosuppression
Systemic corticosteroids 29 52.7
Inhaled corticosteroids 22 40.0
HIV infection 5 9.1
Haematopoietic stem cell therapy 4 7.3
Risk habits
Alcoholic or ex 6 10.9
Smoker or ex 21 38.2
IVDU or ex 3 5.5
Delay to treatment initiation
Symptoms to treatment (days) mean  SDb 11.45  14.01
RX diagnosis to treatment (days) mean  SDc 6.29  11.97
COPD, chronic obstructive pulmonary disease; HCV, hepatitis C virus; IVDU,
intravenous drug user; SD, standard deviation; RX, radiological; CNS, central
nervous system.
a CNS (n = 2), kidney, prostate, rectal, anal, colon.
b Data corresponding to 44 patients.
c Data corresponding to 48 patients.
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nary, disseminated (including central nervous system (CNS)
involvement), and cutaneous (Minero et al., 2009). Human
pulmonary infections are acquired mainly through the respiratory
route by inhalation of the bacteria; however, most infections are
limited to transient colonization, and Nocardia acts as a pathogen
only on some occasions (Brown-Elliott et al., 2006). Pulmonary
nocardiosis at presentation is subacute (Singh et al., 2016) and
usually occurs in immunocompromised patients or in patients
with chronic underlying pulmonary diseases (Kurahara et al.,
2014; Minero et al., 2009; Muñoz et al., 2007; Steinbrink et al.,
2018). Clinically, Nocardia pneumonia is indistinguishable from
pneumonia caused by other infectious agents, making it very
difficult to suspect nocardiosis in the immunocompetent popula-
tion (Fujita et al., 2016; Kim et al., 2016; Steinbrink et al., 2018).
Cell-mediated immunity seems to be crucial for preventing the
dissemination of Nocardia from the portal of entry into the rest of
the body. Consequently, patients on corticosteroid therapy and
those on other therapies or with diseases causing cellular
immunosuppression are at a higher risk of suffering from an
invasive or disseminated Nocardia infection (Kontoyiannis et al.,
1998).
In their report published in 1997, Menendez et al. established
that the diagnosis of pulmonary nocardiosis was difficult and
usually delayed. Moreover, it was frequently disseminated to
other body parts, and a combined, synergistic antimicrobial
treatment as initial therapy was proposed (Menéndez et al.,
1997). Since then, new Nocardia diagnostic and molecular
identification methods, as well as new antibiotics for the
treatment of nocardiosis have been introduced in clinical practice
(McTaggart et al., 2010; Moylett et al., 2003). In this study, all
Nocardia pneumonia cases diagnosed in Spain over a 7-year period
were reviewed, thus providing a large, recent, real-life multicentre
series of this infrequent infection.
Methods
Patients
The study included all cases of Nocardia pneumonia occurring
between 2010 and 2016 in five tertiary Spanish hospitals in three
different cities (Madrid, Barcelona, and San Sebastian). The
inclusion criteria for a case of Nocardia pneumonia were the
presence of a radiological image compatible with pneumonia and a
Nocardia spp cultured from a respiratory secretion and identified
as the pathogen responsible for the infection.
Clinical and microbiological data were reviewed retrospectively
and recorded according to a previously designed questionnaire;
these included the patients’ conditions and risk factors, as
described in Table 1.
Ethics
The work was done according to the regulatory requirements of
the Spanish legislation in force (Ley Organica 3/2018) and data
were processed and analysed anonymously. Publication of the
results of this study was approved by the Clinical Research Ethics
Committee of the Basque Country (reference 2017161).
Microbiological studies
All isolates were presumptively identified as Nocardia according
to their phenotypic growth characteristics. Definitive species
identification was performed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS;
Bruker Daltonics, Germany) after direct transfer–formic acidpreparation and a species cut-off score value of >1.7, or by
sequencing a fragment of the 16S rRNA (Steingrube et al., 1997),
hsp65 (Telenti et al., 1993), and secA1 (Conville et al., 2006) genes.
A  99% similarity with the corresponding sequences of the
reference species available in GenBank (http://www.ncbi.nlm.
nih.gov) was required for species identification (CLSI (Clinical and
Laboratory Standards Institute), 2018).
Susceptibility testing was performed at each of the
participating hospitals by broth microdilution method using
Sensititre microtitre trays (Thermo Fisher, Inc., West Sussex,
UK) or by Etest (AB Biodisk, Solna, Sweden). Staphylococcus
aureus ATCC 29213 was used as control. Antibiotics tested in each
hospital varied, but trimethoprim–sulfamethoxazole (TMP–SMZ),
imipenem, amikacin, linezolid, and ciprofloxacin were tested in all
participating hospitals. Minimum inhibitory concentrations
(MICs) were recorded and interpreted according to the Clinical
and Laboratory Standards Institute (CLSI) interpretative criteria
for Nocardia (CLSI (Clinical and Laboratory Standards Institute),
2011).
Statistical analysis
Frequencies of categorical variables were compared using the
Chi-square test or Fisher’s exact test, as appropriate. A univariate
logistic regression analysis was performed to calculate the
relationship between each of the conditions included in Table 1
and pneumonia mortality. In this analysis, patients who died
because of other causes were excluded. The variables that resulted
in a p-value of <0.20 level of significance were analysed using a
multivariate logistic regression model. The final selection of
variables associated with mortality was made with the backward
stepwise selection method. The statistical analyses were per-
formed using IBM SPSS Statistics version 25.0 (IBM Corp., Armonk,
NY, USA).
Table 2
Annual distribution of the cases of Nocardia pneumonia recorded in five Spanish
hospitals, 2010–2016.
Total 2010 2011 2012 2013 2014 2015 2016 Total
N. abscessus 1 1 2 2 0 0 2 8
N. arthritidis 0 0 0 0 0 1 0 1
N. beijingensis 0 0 0 0 0 0 1 1
N. cyriacigeorgica 3 2 2 4 4 3 3 21
N. farcinica 0 0 1 1 1 1 1 5
N. otitidiscaviarum 2 0 1 0 1 0 0 4
N. pseudobrasiliensis 0 0 1 0 0 0 0 1
N. wallacei 0 1 0 0 0 0 0 1
Nocardia spp 1 3 1 1 0 2 0 8
N. transvalensis 0 2 1 0 0 0 1 4
N. veterana 1 0 0 0 0 0 0 1
Total 8 9 9 8 6 7 8 55
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Overall, 55 patients fulfilled the criteria for Nocardia pneumo-
nia. The average age at the time of infection was 67.5 years (range
23–90 years) and 35 (63.6%) were male.
The number of patients varied greatly among hospitals, from
one to 20. However, the overall number of cases per year was very
homogeneous, ranging from six cases in 2014 to nine cases in 2011
and 2012 (Table 2). Most patients (52/55, 94.5%) had predisposing
respiratory factors for developing pneumonia and many were
immunocompromised as a result of disease or pharmacological
treatment (Table 1).
Clinical manifestations
The average duration of infection from the onset of symptoms
to diagnosis, registered in 24 patients, was 12.9 days (range 2–34
days). Cough and purulent expectoration were the most frequent
clinical manifestations (Table 3).
The infection was disseminated to the CNS in two patients. The
time-to-diagnosis in these two patients was slightly longer than
the average of the rest of the patients (28 and 34 days). The first
case of CNS involvement was a N. cyriacigeorgica infection in a 23-
year-old woman who eventually died because of acute megalo-
blastic leukaemia. The second case was caused by a Nocardia spp
(not identified to the species level) in a 25-year-old man, ex-
intravenous drug user (IVDU), who was infected with hepatitis C
virus (HCV) and HIV and was not on antiretroviral therapy (1 109
leukocytes/l, 1% CD4 count, 91 710 HIV copies/ml). His initial TMP–
SMZ treatment was changed to oral linezolid 600 mg/12 h and
meropenem 2 g/8 h intravenously (IV) due to a cutaneous rash.
Meropenem was replaced after 30 days with ceftriaxone IV 1 g/24 h
and the patient recovered.Table 3
Clinical manifestations in 55 patients with Nocardia pneumonia.
Clinical manifestations Number %
Cough 39 71




Pleuritic pain 11 20
Confusion 5 9.1
Sweating 3 5.5
Weight loss 1 1.8Pulmonary radiological findings
The most common radiological finding was consolidation
(n = 33), followed by nodules (n = 27), cavitation (n = 14), bronchi-
ectasis (n = 6), and infiltrates (n = 4). Fibrotic tracts were observed
in two patients, an interstitial lung pattern in one patient, and
ground glass opacities in one patient.
Consolidation was the only radiological finding in 10 patients;
consolidation was observed together with nodules in eight
patients, with nodules plus cavitation in five patients, with pleural
effusion in three patients, and with cavitation and pleural effusion
in two patients. In total, four patients presented pleural effusion,
three of whom were infected with N. abscessus.
The presence of consolidation with nodules and/or cavitation
was not associated with any specific Nocardia species. Still, seven
out of nine (77.8%) patients with N. farcinica or N. otitidiscaviarum
pneumonia had consolidation with nodules (three and one of them
with cavitation, respectively). However the high presence of
nodules in pneumonia caused by N. farcinica and N. otitidiscaviarum
compared to the rest of the species (18/46, 39.1%) did not reach
statistical significance (p = 0.063). Cavitation was found in 13 of 41
immunocompromised patients and in one of 13 immunocompe-
tent patients (p = 0.146). The two patients with lung carcinoma
showed cavitation; it was not possible to determine whether the
cavitation was due to the carcinoma or to the Nocardia infection.
Treatments and outcomes
The 1-year mortality associated with Nocardia pneumonia was
high: 38.2% (21/55). The 30-day all-cause mortality after a Nocardia
pulmonary diagnosis was 18.2% (10/55). Overall, six deaths were
not directly related to the Nocardia pneumonia but to the
underlying disease: HIV, massive bleeding in a cirrhotic patient,
cardiac insufficiency, leukaemia, anal neoplasia, and astrocytoma.
In the other 15 cases, mortality was related to the lung disease that
occurred in the patients, all of whom were receiving corticoste-
roids at the time of infection (one inhaled, five systemic, and nine
both). Furthermore, seven had chronic obstructive pulmonary
disease (COPD) (one with bronchiectasis and asthma), two only
bronchiectasis, three were on haematopoietic stem cell therapy
(one of whom also had COPD), two had neoplasia (glioblastoma
and pulmonary adenocarcinoma), one had cryptogenic organized
pneumonia, and the last one was an 85-year-old man with no
pulmonary underlying disease but with cardiovascular disease and
hepatomegaly.
To investigate the influence of the different risk factors on
mortality, the six patients who died of causes not directly related to
the pneumonia and one survivor for whom most clinical data were
not available were excluded from the analysis. Of all risk factors
described in Table 1, only four showed a p-value of <0.2 in the
univariate analysis (Table 4). The multivariate analysis demon-
strated that having systemic corticosteroids (p = 0.002) was the
only individual risk factor associated with mortality. The systemic
corticosteroids administered varied greatly between patients in
terms of the type, dosage, and combinations. Twelve patients were
receiving methylprednisolone,11 prednisone, five dexamethasone,
and one deflazacort at the time of infection. Being a smoker or
former smoker, having inhaled corticosteroids, and being on
haematopoietic stem cell therapy, although having a p-value of
<0.2 in the univariate analysis, did not show an association with
mortality in the multivariate analysis (p = 0.376, p = 0.383,
p = 0.106, respectively). A delay in initiating the antibiotic
treatment, from symptom onset or from radiological diagnosis,
was not associated with mortality in the univariate analysis
(p = 0.459 and p = 0.535, respectively).
Table 4
Significant risk factors for mortality in the logistic regression analyses (n = 48).
Univariatea Multivariable
Variable OR 95% CI p-Value OR 95% CI p-Value
Inhaled corticosteroids 4.00 1.10 to 14.60 0.036 - - -
Systemic corticosteroids 28.00 3.25 to 241.34 0.002 28.00 3.25 to 241.34 0.002
Haematopoietic stem cell therapy 8.00 0.76 to 84.59 0.084 - - -
Current smoker or ex-smoker 2.63 0.75 to 9.24 0.132 - - -
OR, odds ratio; CI, confidence interval. Data are shown as the estimated OR (95% CI) of the explanatory variables in the mortality group. OR is defined as the probability of being
in the mortality group divided by the probability of being in the non-mortality group. The p-values are based on the null hypothesis that all ORs relating to an explanatory
variable equal unity (no effect).
a The variables analysed in the univariate analysis were those described in Table 1.
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treatment was 6.3 months (range 3–13 months, median 6 months).
Forty-three patients were treated with TMP–SMZ, either alone (23
patients) or in combination (20 patients) with other antibiotics.
The most frequent combination was TMP–SMZ with imipenem/
meropenem (11 patients), in five of them also with amikacin.
Linezolid was used in three patients (alone in two patients and in
combination with meropenem in one patient) due to secondary
effects to TMP–SMZ (rash and renal tubular acidosis) or in vitro
suspected Nocardia TMP–SMZ resistance. In the two patients
treated with linezolid alone, the duration of treatment was
5 months and 7 months, respectively. The first patient had to stop
his treatment because of polyneuropathy, but was considered
cured.
Excluding the six deaths not directly related to the Nocardia
pneumonia, there was no difference in the survival of patients with
pulmonary nocardiosis treated with only TMP–SMZ compared toTable 5
Susceptibility criteria and range, MIC50 and MIC90, and number of susceptible isolates of
2016.
Species Number Amikacin 
Susceptible criteria 8 
























MIC, minimum inhibitory concentration; TMP–SMZ, trimethoprim–sulfamethoxazole.
a Number of susceptible isolates of all tested.
b Including 21 N. cyriacigeorgica, 8 N. abscessus, 5 N. farcinica, 4 N. otitidiscaviarum, 4
veterana.other antibiotic treatments: 5/15 (33.3%) patients died and 15/34
(44.1%) survived (p = 0.54).
Antimicrobial susceptibility
The Nocardia was isolated from the sputum of 42 patients, from
the bronchoalveolar lavage or aspirate (BAL/BAS) of 10 patients,
and from the tracheal aspirate, transthoracic biopsy, and pleural
fluid of one patient each.
Antimicrobial susceptibility results were available for 49
isolates, with all being susceptible to linezolid and all but two,
one N. farcinica and one N. otitidiscaviarum, being susceptible to
amikacin (Table 5). There were two TMP–SMZ-resistant isolates:
one N. otitidiscaviarum and one Nocardia spp (not identified to the
species level). Half of the N. abscessus and N. otitidiscaviarum were
imipenem-resistant, while nearly all isolates of other species were
susceptible to carbapenems. Fluoroquinolones were the antibiotics the Nocardia species most frequently found in cases of pneumonia in Spain, 2010–
Ciprofloxacin Imipenem Linezolid TMP–SMZ
1 4 8 2/38
1–>4 2–64 1–2 0.25–1
>4 2 1 0.25
>4 4 1 1
2/20 19/21 21/21 21/21
0.12–>4 2–>64 1 0.25–0.5
4 4 1 0.25
>4 >64 1 0.5
1/7 4/8 7/7 8/8
1–4 2–>64 1–4 0.5–2
4 2 1 0.5
>4 12 4 2
1/4 2/4 5/5 5/5
1–>4 2–32 0.5–2 0.25–4
1 2 0.5 0.5
>4 32 2 4
2/4 2/4 4/4 3/4
0.25–>4 2 1 0.25–0.5
0.25 2 1 0.25
>4 2 1 0.5
3/4 4/4 4/4 4/4
2–64 2–>64 1–4 0.25–32
>4 2 1 0.25
>4 64 1 2
11/45 31/41 47/47 47/49
 N. transvalensis, 4 Nocardia spp, and one each N. arthritidis,N. beijingensis, and N.
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due to the predominance of N. cyriacigeorgica infections in the
population of this study.
Discussion
The respiratory tract is the main portal of entry for Nocardia,
and as a consequence, around 50% to 70% of nocardiosis patients
have pulmonary involvement (Ambrosioni et al., 2010; Hashemi-
Shahraki et al., 2015; Minero et al., 2009; Uhde et al., 2010).
Pulmonary nocardiosis has a low incidence, and the incidence in
Spain has been maintained at a regular level over the past decade
(Minero et al., 2009). In this study, performed between 2010 and
2016, the incidence of pulmonary nocardiosis varied greatly among
hospitals, from one to 20 cases. However, the total number of
annual cases was quite uniform, without the presence of any
outbreak. N. cyriacigeorgica was the most prevalent species causing
pneumonia, followed by N. abscessus and N. farcinica, a species
distribution similar to other Spanish studies (Minero et al., 2009;
Portolá et al., 2009; Valdezate et al., 2017). The absence of any
pulmonary infection caused by N. nova was surprising, as this
species is common in Spain and other countries (Lebeaux et al.,
2019; Uhde et al., 2010; Valdezate et al., 2017).
Pulmonary nocardiosis commonly affects debilitated patients
with predisposing conditions, especially those who are immuno-
compromised due to organ transplantation and/or corticosteroid
treatment and COPD patients (Ambrosioni et al. 2010; Singh et al.,
2016; Steinbrink et al., 2018; Takiguchi et al., 2017; Ott et al., 2019). In
the present study, all 55 patients with Nocardia pneumonia had an
immunological or respiratory predisposing factor. Overall mortality
(38.2%) and mortality directly related to Nocardia pneumonia
(27.3%) was between the 18.9% and 56.7% mortality described in
similar series (Muñoz et al., 2007; Singh et al., 2016; Steinbrink et al.,
2018; Takiguchi et al., 2017; Ott et al., 2019). Systemic corticosteroid
therapy was the only individual risk factorassociatedwith mortality
in the univariate and multivariate analysis. Some authors have not
found any differences in the treatment outcome between immu-
nocompetent and immunocompromised patients (Kim et al., 2016),
although in other works an increase in the rate of disseminated
infections and higher mortality have been observed in immuno-
compromised patients (Steinbrink et al., 2018).
Radiological findings inpatients with pulmonary nocardiosis didnot
differ from those of patients with pneumonia caused by other
respiratory pathogens, except for the presence of nodules in 26 of
the 55 patients, a common radiological picture described previously
(Singhetal.,2016;Steinbrinketal.,2018;Yangetal.,2014).Noduleswere
not significantly more frequent in pneumonia caused by any particular
Nocardia species, although N. farcinica and N. otitidiscaviarum
showed a tendency towards causing nodules more commonly.
Other studies have found an increased proportion of cavitation in
immunocompromised hosts (Kim et al., 2016; Steinbrink et al.,
2018). In the present study, although all but one of the 14 patients
with cavitation were immunocompromised, this difference was not
significant compared to immunocompetent patients.
Clinical manifestations were very similar to those observed in
pneumonia of other aetiologies, except for the lack of fever in more
than half of the patients, which could be suggestive of pulmonary
nocardiosis (Steinbrink et al., 2018). Despite the high rate of
immunocompromised patients, disseminated infections were
identified in only two patients, both in the CNS, a rate similar to
that described by Kurahara et al. (2014), but much lower than is
commonly observed (Ott et al., 2019; Singh et al., 2016; Steinbrink
et al., 2018). In these two severely immunocompromised patients,
the time-to-diagnosis was around 1 month, a delay that could have
favoured dissemination of the infection to the brain.No association between mortality and a delay in initiating
the antibiotic treatment was observed, which has been
suggested in other works as a risk factor for developing
Nocardia pneumonia (Singh et al., 2016; Yang et al., 2014). TMP–
SMZ resistance has also been identified as an independent and
significant risk factor for overall mortality in pulmonary nocar-
diosis (Kurahara et al., 2014). In our study, TMP–SMZ was the
treatment used for most patients, either alone or in combination
with carbapenems or amikacin, despite which the mortality rate
was high. As in other studies (Muñoz et al., 2007), patient
outcomes were not related to the antibiotic prescribed, which
suggests that in the prognosis of Nocardia pneumonia, other
factors such as underlying diseases or clinical and immunological
status at the time of infection have more influence than the
antibiotics used in the treatment.
Most Nocardia isolates causing pneumonia showed in vitro
susceptibility to the majority of antimicrobials used for treatment,
such as linezolid or TMP–SMZ. Imipenem resistance was strongly
related to N. abscessus and N. otitidiscaviarum, while nearly all
isolates of other species were susceptible, as has been described
previously (Larruskain et al., 2011; Muñoz et al., 2007; Uhde et al.,
2010). Most Nocardia isolates – 75.6% – were ciprofloxacin-
resistant, a percentage of resistance higher than reported in the
United States (Uhde et al., 2010), but similar to reports from Spain
(Larruskain et al., 2011). In contrast, the prevalence of TMP–SMZ
resistance, at 4.1%, was lower than the 10.8–42% described in some
studies (Minero et al., 2009; Uhde et al., 2010; Valdezate et al.,
2017). Although N. farcinica is among the species more frequently
resistant to TMP–SMZ (Minero et al., 2009; Kurahara et al., 2014;
Valdezate et al., 2017), in the present study all five N. farcinica
isolates were susceptible.
The main limitation of this study is its retrospective design,
which meant that some cases could have been lost, and some data,
like the species identification or the antimicrobial susceptibility of
some of the isolates, could not be determined. Also, the
retrospective design made it impossible to evaluate the severity
of COPD in patients with this disease and consequently the
influence of Nocardia pulmonary infections in their outcomes. The
stringent conditions used for patient recruitment (presence of
radiologically confirmed pneumonia and the isolation of a Nocardia
in good quality respiratory samples) could have biased the study
towards more ill patients, excluding milder cases of Nocardia
pneumonia in the population with fewer underlying conditions.
Finally, the low number of cases for the statistical analyses, the
wide range of the confidence intervals, and the low numbers of
variables included in the multivariate analysis imply that the
results should be interpreted with caution.
In conclusion, this study gathered one of the largest series of
Nocardia pneumonia, which usually occurs in patients with
underlying pulmonary conditions or immunosuppression. The
progression of disease was not associated with the antibiotic
therapy used. In Spain, N. cyriacigeorgica was the most prevalent
species causing pneumonia and was susceptible to most antibiotics
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